MCID: INT079
MIFTS: 54

Intrahepatic Cholangiocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Intrahepatic Cholangiocarcinoma

MalaCards integrated aliases for Intrahepatic Cholangiocarcinoma:

Name: Intrahepatic Cholangiocarcinoma 12 53 6 15 17 72
Cholangiocarcinoma 44 72
Peripheral Intrahepatic Cholangiocarcinoma 72
Intrahepatic Bile Duct Carcinoma 12
Peripheral Cholangiocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4928
MeSH 44 D018281
NCIt 50 C35417
ICD10 33 C22.1
UMLS 72 C0206698 C0345905 C3273048

Summaries for Intrahepatic Cholangiocarcinoma

NIH Rare Diseases : 53 Intrahepatic cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. The terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. This condition occurs slightly more often in males than females and usually affects people who are between 50-70 years old. Signs and symptoms of intrahepatic cholangiocarcinoma include jaundice, abdominal pain, fever, weight loss, weakness and itching. Treatment options may include surgery to remove the bile duct and parts of the liver, chemotherapy and radiation.

MalaCards based summary : Intrahepatic Cholangiocarcinoma, also known as cholangiocarcinoma, is related to cholangiocarcinoma and bile duct adenoma, and has symptoms including abdominal pain and malaise. An important gene associated with Intrahepatic Cholangiocarcinoma is CCAT1 (Colon Cancer Associated Transcript 1), and among its related pathways/superpathways are MicroRNAs in cancer and mTOR signaling pathway (KEGG). The drugs Celecoxib and Desflurane have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and colon, and related phenotype is neoplasm.

Related Diseases for Intrahepatic Cholangiocarcinoma

Diseases related to Intrahepatic Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 634)
# Related Disease Score Top Affiliating Genes
1 cholangiocarcinoma 32.9 TUG1 TP53 MUC4 MUC1 KRT7 KRAS
2 bile duct adenoma 31.8 MUC1 KRT7
3 adenocarcinoma 31.6 TP53 MUC4 MUC1 KRAS FGFR2 APC
4 papillary adenocarcinoma 31.5 TP53 MUC1 KRT7
5 cystadenocarcinoma 31.3 TP53 MUC1 KRT7
6 colorectal adenocarcinoma 31.2 TP53 KRT7 KRAS
7 biliary papillomatosis 31.1 TP53 MUC1 KRT7 KRAS
8 intrahepatic bile duct adenoma 31.1 KRT7 AFP
9 mucinous adenocarcinoma 31.0 MUC1 KRT7 KRAS
10 cystadenoma 31.0 MUC4 MUC1 KRT7
11 undifferentiated pleomorphic sarcoma 31.0 KRAS IDH2 IDH1
12 bile duct cystadenocarcinoma 31.0 MUC1 KRT7 AFP
13 familial adenomatous polyposis 30.9 TP53 KRAS APC
14 carcinosarcoma 30.9 TP53 MUC1 KRT7 KRAS
15 adenosquamous carcinoma 30.7 TP53 MUC4 MUC1 KRT7 KRAS
16 ampulla of vater cancer 30.7 TP53 MUC1 KRT7 KRAS
17 adenomyoma 30.7 MUC4 MUC1 KRT7
18 bronchiolo-alveolar adenocarcinoma 30.6 MUC4 KRT7 KRAS
19 gallbladder cancer 30.6 TUG1 TP53 MUC1 KRAS CCAT1
20 pancreatic ductal carcinoma 30.6 TP53 MUC1 KRT7
21 squamous cell carcinoma 30.5 TUG1 TP53 MUC1 FGFR2 CCAT2
22 glioblastoma 30.5 TUG1 TP53 IDH2 IDH1 FGFR2
23 dysgerminoma 30.4 KRT7 FGFR2 AFP
24 hepatoblastoma 30.4 TUG1 TP53 KRT7 APC AFP
25 gastrointestinal system cancer 30.4 TP53 KRT7 KRAS AFP
26 renal cell carcinoma, nonpapillary 30.3 TUG1 MUC1 KRT7 CCAT1
27 bile duct adenocarcinoma 30.1 TP53 MUC1 KRT7 KRAS IDH2 IDH1
28 osteogenic sarcoma 30.0 TUG1 TP53 CCAT2 CCAT1
29 gastric adenocarcinoma 29.9 TP53 MUC4 MUC1 KRT7 KRAS FGFR2
30 gastrointestinal system disease 29.9 TP53 KRAS AFP
31 kidney cancer 29.9 TP53 MIR424 MIR214
32 endometrial cancer 29.8 TUG1 TP53 KRT7 KRAS FGFR2 CCAT1
33 clear cell renal cell carcinoma 29.8 TUG1 TP53 PBRM1 MUC1 KRT7 CCAT2
34 lung squamous cell carcinoma 29.6 TUG1 TP53 KRAS FGFR2 CCAT2 CCAT1
35 bladder cancer 29.6 TUG1 TP53 MIR127 KRAS CCAT2
36 myeloma, multiple 29.5 TUG1 TP53 KRAS IDH2 IDH1 CCAT1
37 lung cancer susceptibility 3 29.3 TUG1 TP53 MUC4 MUC1 KRT7 KRAS
38 colorectal cancer 29.0 TUG1 TP53 MUC1 MIR127 KRT7 KRAS
39 gastric cancer 28.9 TUG1 TP53 MIR214 KRAS FGFR2 CCAT2
40 prostate cancer 27.8 TUG1 TP53 MIR22 MIR214 MIR127 KRAS
41 breast cancer 27.6 TUG1 TP53 MUC1 MIR22 MIR127 KRAS
42 hepatocellular carcinoma 27.5 TUG1 TP53 MIR22 MIR214 MIR127 KRT7
43 pancreatic cancer 27.4 TUG1 TP53 MUC4 MUC1 MIR424 MIR376A1
44 lung cancer 26.9 TUG1 TP53 MUC4 MIR22 MIR214 KRT7
45 ovarian cancer 26.2 TUG1 TP53 MUC1 MIR424 MIR376A1 MIR214
46 mucinous intrahepatic cholangiocarcinoma 12.6
47 sarcomatous intrahepatic cholangiocarcinoma 12.6
48 signet ring cell intrahepatic cholangiocarcinoma 12.5
49 klatskin's tumor 11.8
50 interval angle-closure glaucoma 10.8 IDH2 IDH1

Graphical network of the top 20 diseases related to Intrahepatic Cholangiocarcinoma:



Diseases related to Intrahepatic Cholangiocarcinoma

Symptoms & Phenotypes for Intrahepatic Cholangiocarcinoma

UMLS symptoms related to Intrahepatic Cholangiocarcinoma:


abdominal pain, malaise

MGI Mouse Phenotypes related to Intrahepatic Cholangiocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 AFP APC FGFR2 IDH2 KRAS TP53

Drugs & Therapeutics for Intrahepatic Cholangiocarcinoma

Drugs for Intrahepatic Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 326)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
Desflurane Approved Phase 4 57041-67-5 42113
3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
4
Etomidate Approved Phase 4 33125-97-2 36339 667484
5 Anti-Inflammatory Agents, Non-Steroidal Phase 4
6 Cyclooxygenase Inhibitors Phase 4
7 Cyclooxygenase 2 Inhibitors Phase 4
8 Anesthetics, Inhalation Phase 4
9 Platelet Aggregation Inhibitors Phase 4
10 Analgesics Phase 4
11
Bismuth Phase 4 7440-69-9 16682734 105143
12 Ulipristal acetate Phase 4 126784-99-4
13 Omega 3 Fatty Acid Phase 4
14 arginine Phase 4
15 Narcotics Phase 4
16 Central Nervous System Depressants Phase 4
17 Analgesics, Opioid Phase 4
18 Hypnotics and Sedatives Phase 4
19 Anesthetics, General Phase 4
20 Anesthetics, Intravenous Phase 4
21 GABA Agents Phase 4
22 GABA Modulators Phase 4
23 Tranquilizing Agents Phase 4
24 Anti-Anxiety Agents Phase 4
25 Adjuvants, Anesthesia Phase 4
26
Irinotecan Approved, Investigational Phase 2, Phase 3 100286-90-6, 97682-44-5 60838
27
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
28
Ivosidenib Approved, Investigational Phase 3 1448347-49-6 71657455
29
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
30
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
31
Pembrolizumab Approved Phase 3 1374853-91-4
32
Fluorouracil Approved Phase 3 51-21-8 3385
33
leucovorin Approved Phase 3 58-05-9 143 6006
34
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
35
Citalopram Approved Phase 3 59729-33-8 2771
36
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
37
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
38
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
39 Antacids Phase 3
40 Anti-Ulcer Agents Phase 3
41 Antiparasitic Agents Phase 3
42 Anthelmintics Phase 3
43 Pharmaceutical Solutions Phase 3
44 Mitogens Phase 3
45 Calcium, Dietary Phase 2, Phase 3
46 Hematinics Phase 3
47 Micronutrients Phase 3
48 Trace Elements Phase 3
49 Vitamins Phase 3
50 Nutrients Phase 3

Interventional clinical trials:

(show top 50) (show all 515)
# Name Status NCT ID Phase Drugs
1 Effect of Preoperative Biliary Drainage on Postoperative Complications in Resectable Patients With Hilar Cholangiocarcinoma(Klatskin Tumor) Unknown status NCT00797121 Phase 4
2 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent: A Randomized Control Trial Unknown status NCT00746538 Phase 4
3 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
4 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
5 Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
6 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Unresectable Complex Hilar Cholangiocarcinoma; a Randomized Controlled Trial Completed NCT00721175 Phase 4
7 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
8 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
9 Pilot Study: Randomized Controlled Trial on the Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
10 Re-intervention for Occluded Biliary Metal Stent in Malignant Distal Bile Duct Obstruction: a Prospective Randomized Multi-center Trial Comparing Covered and Uncovered Metal Stent Completed NCT01315522 Phase 4
11 Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP) Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
12 Endoscopic Radiofrequency Ablation for Malignant Biliary Obstruction Completed NCT01758341 Phase 4
13 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Recruiting NCT01642875 Phase 4
14 Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma Unknown status NCT02548195 Phase 3 oxaliplatin and gemcitabine;capecitabine
15 A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
16 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
17 Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures: A Prospective, Multi-center Randomized Controlled Trial Unknown status NCT00653978 Phase 3
18 Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma. Unknown status NCT01755013 Phase 2, Phase 3
19 A Prospective, Randomized Trial of Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
20 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
21 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
22 Photodynamic Therapy With S-1 in the Patients With Unresectable Type III or IV Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control Completed NCT00869635 Phase 3 S-1 Chemotherapy
23 Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
24 Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study Completed NCT00513539 Phase 3 porfimer sodium
25 Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma Completed NCT01640522 Phase 3
26 Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
27 Sequential Preoperative Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization to Induce Further Liver Regeneration in Patients With Hepatobiliary Malignancy Completed NCT00698880 Phase 2, Phase 3
28 The Efficacy of Levamisole Hcl in Advanced Intrahepatic Cholangiocarcinoma . A Multicenter, Open, Randomized, Prospective Study Recruiting NCT03940378 Phase 3 Levamisole Hydrochloride;Anlotinib Hydrochloride Capsules
29 Hepatic Arterial Infusion Chemotherapy of Gemcitabine, Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Systemic Chemotherapy of Gemcitabine and Oxaliplatin for Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT03771846 Phase 3 gemcitabine, oxaliplatin , fluorouracil, and leucovorin;gemcitabine and oxaliplatin
30 Bortezomib in Treating Patients With Intrahepatic Cholangiocellular Carcinoma Featuring PTEN Deficiency Recruiting NCT03345303 Phase 3 Bortezomib
31 Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT02807181 Phase 2, Phase 3 Cisplatin-gemcitabine
32 Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma Recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
33 A Randomized, Open, Multi-center Phase IIb/III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Capecitabine in Advanced or Metastatic Biliary Tract Carcinoma (BTC) Patients Recruiting NCT03873532 Phase 2, Phase 3 Surufatinib;Capecitabine
34 A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial Recruiting NCT03773302 Phase 3 BGJ398;Gemcitabine;Cisplatin
35 A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302) Recruiting NCT03656536 Phase 3 Pemigatinib;Gemcitabine;Cisplatin
36 Percutaneous Bilateral Versus Unilateral Metal Stent Placement for Hilar Cholangiocarcinoma : A Prospective Open-label Randomized Controlled Trial Recruiting NCT02108145 Phase 2, Phase 3
37 Phase III Randomized Trial of High Dose Chemoradiation and Systemic Chemotherapy vs Systemic Chemotherapy Alone in Patients With Unresectable Nonmetastatic Cholangiocarcinoma Recruiting NCT02773485 Phase 3 Systemic chemotherapy
38 Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
39 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
40 Phase III Randomized, Placebo-controlled Clinical Trial of Hepcortespenlisimut-L (Hepko-V5) Versus Placebo in Patients With Advanced Hepatocellular Carcinoma (HCC) Recruiting NCT02232490 Phase 3
41 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
42 Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
43 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial Recruiting NCT02853474 Phase 3
44 Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Active, not recruiting NCT02482454 Phase 2, Phase 3
45 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation Active, not recruiting NCT02989857 Phase 3 AG-120;AG-120 matched placebo
46 A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of GEMOX(Gemcitabine/Oxaliplatin) vs XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Active, not recruiting NCT01470443 Phase 3 Oxaliplatin;Oxaliplatin
47 A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy. Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
48 Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies Active, not recruiting NCT02349412 Phase 3
49 Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (ICC/ECC) - A Phase III Study of the German Registry of Incidental Gallbladder Carcinoma Platform (GR) - The AIO/ CALGP/ ACO- GAIN-Trial - Not yet recruiting NCT03673072 Phase 3 Gemcitabine;Cisplatin;Adjuvant chemotherapy
50 Single-center, Single-arm and Phase II/III Clinical Study of Paclitaxel (Albumin-binding) Combined With Oxaliplatin as First-line Treatment for Advanced Hepatobiliary and Malignant Tumors Not yet recruiting NCT04060472 Phase 2, Phase 3 albumin-bound paclitaxel + oxaliplatin

Search NIH Clinical Center for Intrahepatic Cholangiocarcinoma

Cochrane evidence based reviews: cholangiocarcinoma

Genetic Tests for Intrahepatic Cholangiocarcinoma

Anatomical Context for Intrahepatic Cholangiocarcinoma

MalaCards organs/tissues related to Intrahepatic Cholangiocarcinoma:

41
Liver, Lymph Node, Colon, T Cells, Pancreas, Lung, Breast

Publications for Intrahepatic Cholangiocarcinoma

Articles related to Intrahepatic Cholangiocarcinoma:

(show top 50) (show all 11214)
# Title Authors PMID Year
1
MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. 38 88
19755794 2009
2
Gold nano particles synthesized from Strychni semen and its anticancer activity in cholangiocarcinoma cell (KMCH-1). 38
31072209 2019
3
UHRF1 is regulated by miR-124-3p and promotes cell proliferation in intrahepatic cholangiocarcinoma. 38
30989656 2019
4
Downstaging Locally Advanced Cholangiocarcinoma Pre-Liver Transplantation: A Prospective Pilot Study. 38
31059945 2019
5
A review on co-existent Epstein-Barr virus-induced complications in inflammatory bowel disease. 38
31205127 2019
6
Evaluation of the AJCC 8th Edition Staging System for Pathologically Versus Clinically Staged Intrahepatic Cholangiocarcinoma (iCCA): a Time to Revisit a Dogma? A Surveillance, Epidemiology, and End Results (SEER) Analysis. 38
29512000 2019
7
Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features. 38
31017316 2019
8
CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. 38
31059778 2019
9
Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged. 38
31014988 2019
10
Three-Dimensional Printing Facilitates Creation of a Biliary Endoscopy Phantom for Interventional Radiology-Operated Endoscopy Training. 38
30477812 2019
11
Sample size calculation for small sample single-arm trials for time-to-event data: Logrank test with normal approximation or test statistic based on exact chi-square distribution? 38
31080909 2019
12
Cholangiographic Tumor Classification for Simple Patient Selection Prior to Hepatopancreatoduodenectomy for Cholangiocarcinoma. 38
31102092 2019
13
Inflammatory Myofibroblastic Tumor of the Mid Common Bile Duct Masquerading as Cholangiocarcinoma. 38
29453762 2019
14
ASO Author Reflections: Which Patients Benefit the Most From Lymphadenectomy During Resection for Intrahepatic Cholangiocarcinoma? 38
31286308 2019
15
Sarcopenia Affects Systemic and Local Immune System and Impacts Postoperative Outcome in Patients with Extrahepatic Cholangiocarcinoma. 38
31041559 2019
16
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. 38
31300360 2019
17
Race, ethnicity, and socioeconomic factors in cholangiocarcinoma: What is driving disparities in receipt of treatment? 38
31301148 2019
18
Therapeutic Index Associated with Lymphadenectomy Among Patients with Intrahepatic Cholangiocarcinoma: Which Patients Benefit the Most from Nodal Evaluation? 38
31152272 2019
19
lncRNA FLVCR1-AS1 regulates cell proliferation, migration and invasion by sponging miR-485-5p in human cholangiocarcinoma. 38
31404302 2019
20
Targeted therapy for cholangiocarcinoma. 38
31300361 2019
21
Hybrid Laparoscopic and Robotic Hepatopancreaticoduodenectomy for Cholangiocarcinoma. 38
31197693 2019
22
Occult synchronous liver metastasis from perihilar cholangiocarcinoma. 38
31235246 2019
23
Prognostic Impact of Tumor Multinodularity in Intrahepatic Cholangiocarcinoma. 38
30478531 2019
24
Tumor Budding in Intrahepatic Cholangiocarcinoma: A Predictor of Postsurgery Outcomes. 38
31335353 2019
25
Anticancer activity of synthetic (±)-kusunokinin and its derivative (±)-bursehernin on human cancer cell lines. 38
31220743 2019
26
Problematic lesions in cirrhotic liver mimicking hepatocellular carcinoma. 38
30788586 2019
27
Coming of a precision era of the staging systems for intrahepatic cholangiocarcinoma? 38
31212000 2019
28
Indications for Single-Operator Cholangioscopy and Pancreatoscopy: an Expert Review. 38
31165382 2019
29
Prognostic Factors and the Role of Adjuvant Treatment in Periampullary Carcinoma: a Single-Centre Experience of 95 Patients. 38
29464529 2019
30
The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma. 38
31053477 2019
31
Diagnostic yield of endoscopic ultrasonography for a dilation of the common bile duct of an indeterminate cause. 38
31373506 2019
32
Postoperative Pancreatic Fistula in Surgery for Perihilar Cholangiocarcinoma. 38
31407095 2019
33
Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. 38
31405908 2019
34
Split-bolus vs. multiphasic contrast bolus protocol in patients with pancreatic cancer or cholangiocarcinoma. 38
31430661 2019
35
APEX1 Expression as a Potential Diagnostic Biomarker of Clear Cell Renal Cell Carcinoma and Hepatobiliary Carcinomas. 38
31375000 2019
36
Temporary Balloon Occlusion for Hepatic Arterial Flow Redistribution during Yttrium-90 Radioembolization. 38
31155499 2019
37
Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. 38
30618056 2019
38
Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines. 38
31382694 2019
39
Double-balloon enteroscopy-facilitated cyanoacrylate-injection endotherapy of small-bowel varices: an international experience from 2 European tertiary centers (with videos). 38
30980796 2019
40
LINC01503 promotes cell proliferation, invasion and EMT process in cholangio-carcinoma. 38
31378883 2019
41
Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. 38
31383016 2019
42
Prognostic utility of albumin-bilirubin grade for short- and long-term outcomes following hepatic resection for intrahepatic cholangiocarcinoma: A multi-institutional analysis of 706 patients. 38
31025380 2019
43
Silencing of LAMC2 Reverses Epithelial-Mesenchymal Transition and Inhibits Angiogenesis in Cholangiocarcinoma via Inactivation of the Epidermal Growth Factor Receptor Signaling Pathway. 38
31345467 2019
44
Expression of fatty-acid-binding protein 5 in intrahepatic and extrahepatic cholangiocarcinoma: the possibility of different energy metabolisms in anatomical location. 38
31432248 2019
45
Corrigendum to "Induction of phosphatase shatterproof 2 by evodiamine suppresses the proliferation and invasion of human cholangiocarcinoma" [Int. J. Biochem. Cell Biol. 108 (2019) 98-110]. 38
30910281 2019
46
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. 38
31088831 2019
47
Mixed adenoendocrine carcinoma in the extrahepatic biliary tract: A case report and literature review. 38
31423226 2019
48
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. 38
31276980 2019
49
Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink. 38
30448774 2019
50
CT reconstruction algorithms affect histogram and texture analysis: evidence for liver parenchyma, focal solid liver lesions, and renal cysts. 38
30456584 2019

Variations for Intrahepatic Cholangiocarcinoma

ClinVar genetic disease variations for Intrahepatic Cholangiocarcinoma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 APC NM_000038.6(APC): c.8332G> T (p.Ala2778Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs587778046 5:112179623-112179623 5:112843926-112843926
2 APC NM_000038.6(APC): c.4440G> C (p.Gln1480His) single nucleotide variant Uncertain significance rs876659881 5:112175731-112175731 5:112840034-112840034
3 APC NM_000038.6(APC): c.8461G> A (p.Asp2821Asn) single nucleotide variant Uncertain significance rs1554089164 5:112179752-112179752 5:112844055-112844055

Expression for Intrahepatic Cholangiocarcinoma

Search GEO for disease gene expression data for Intrahepatic Cholangiocarcinoma.

Pathways for Intrahepatic Cholangiocarcinoma

Pathways related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.11 TP53 MIR214 KRAS APC
2
Show member pathways
12.02 TP53 KRAS FGFR2 APC
3
Show member pathways
12.02 TP53 PBRM1 KRAS FGFR2 APC
4 11.59 TP53 KRAS APC
5 10.76 TP53 KRAS IDH1 FGFR2
6
Show member pathways
10.27 IDH2 IDH1

GO Terms for Intrahepatic Cholangiocarcinoma

Biological processes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cellular senescence GO:2000774 9.37 MIR22 KRAS
2 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.33 MUC4 MUC1 KRAS
3 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.32 TP53 MUC1
4 NADP metabolic process GO:0006739 9.26 IDH2 IDH1
5 isocitrate metabolic process GO:0006102 8.96 IDH2 IDH1
6 glyoxylate cycle GO:0006097 8.62 IDH2 IDH1

Molecular functions related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 isocitrate dehydrogenase activity GO:0004448 8.96 IDH2 IDH1
2 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.62 IDH2 IDH1

Sources for Intrahepatic Cholangiocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....